Adherence to drug therapy in patients with chronic coronary heart disease after percutaneous coronary interventions

Cover Page

Cite item

Full Text

Abstract

Background. Poor patient adherence to drug therapy (DT) for stable coronary heart disease (CHD) is an equally important component that affects treatment outcomes. Aim. To assess adherence to DT in patients with stable coronary heart disease in patients after percutaneous coronary interventions (PCI), compare with patients who received only DT. Materials and methods. The study included 150 patients with CHD (group 1) who underwent PCI surgery at the Tyumen cardiology research center. The comparison group (group 2) consisted of 150 patients with stable CHD, receiving only DT. All patients were diagnosed with CHD and underwent coronary angiography in the anamnesis. The follow-up period was 30.8 months in both groups (8 months to 69 months). The groups of patients were comparable in the main indicators: sex, age, total cholesterol level, presence of concomitant arterial hypertension and diabetes mellitus, functional class (FC) of angina pectoris and heart failure, hemodynamically significant lesion of the main coronary arteries and arteries of the second order, the type of blood circulation and the number of affected vessels at the time of inclusion in the study. Patients of both groups were comparable in conservative therapy. Statistical analysis of the results was carried out using the statistical software package SPSS. Results. In the PCI group, FC of angina pectoris was higher, while in the MT group, III FC was more often registered. This reflects the positive effect of PCI on exercise tolerance. When analyzing regularly taken medications, it was determined that patients who underwent PCI were more likely to use all groups of drugs. On a face-to-face visit, biochemical blood tests for cholesterol spectrum were carried out. Attention is drawn to the low turnout of patients in the DT group compared to the PCI group. The target level of low-density lipoprotein (LDL) was not achieved in both groups, but due to greater adherence to statins in the PCI group, LDL was 0.7 mmol lower than in the DT group. Conclusion. PCI surgery in patients with CHD can not only improve the quality of stress angina pectoris, but also significantly increase adherence to the treatment of the main groups of drugs (statins and antiplatelets) that affect the prognosis.

About the authors

Liudmila I. Gapon

Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

д-р мед. наук, проф., зав. научным отд. клинической кардиологии, науч. рук. отд. артериальной гипертонии, врач-кардиолог высшей категории Tyumen, Russia

Elena P. Samoilova

Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

Email: samoilova_elena1985@mail.ru
врач -кардиолог Tyumen, Russia

Ivan S. Bessonov

Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

канд. мед. наук, зав. лаб. рентгенэндоваскулярных методов диагностики и лечения научного отд. инструментальных методов исследования, науч. сотр. Tyumen, Russia

Elena P. Gultyaeva

Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

канд. мед. наук, зав. отд-нием, врач-кардиолог высшей категории Tyumen, Russia

Svetlana G. Berdinsky

Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

канд. мед. наук, врач-кардиолог высшей категории Tyumen, Russia

References

  1. Соболева М.С. Факторы приверженности к терапии сердечно-сосудистых заболеваний по данным современных исследований. Клиницист. 2017; 11 (2); 33-7.
  2. Каграманян И.Н. Значение комплаенса в повышении качества медицинской помощи. Ремедиум. 2015; 5: 9-25.
  3. Помешкина С.А., Беззубова В.А., Аргунова Ю.А., Барбараш О.Л. Приверженность к комплексой реабилитации после коронарного шунтирования проблема пациента или врача? Медицина в Кузбасее. 2018; 17 (4): 46-50.
  4. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/Guideline on the Management of Blood Cholesterol. Circulation 2019;139:1082-143.
  5. ESC pocket guidelines committee for Practice Guidelines CCS Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019; 00: 1-71.
  6. ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2018; 00: 1-96.
  7. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6-31. doi: 10.26442/2075082X.2019.1.190179
  8. ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J 2018; 39 (33): 3021-104.
  9. Smith DH, O’Keeffe-Rosetti M, Owen Smith AA et al. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial. Value Health 2016; 19 (2): 176-84.
  10. Awad A, Osman N, Altayib S. Medication adherence among cardiac patients in Khartoum State, Sudan: a cross-sectional study. Cardiovasc J Afr 2017; 28: 1-7.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies